Psyence Biomedical (PBM) Income from Continuing Operations (2023 - 2025)

Psyence Biomedical (PBM) recorded quarterly Income from Continuing Operations of 1504977.0 in Q3 2025, down 230.18% quarter-over-quarter from 1156102.0 in Q3 2024, and down 230.18% on a YoY basis from 1156102.0 in Q3 2024.

Psyence Biomedical (PBM) Income from Continuing Operations (2023 - 2025) Analysis & Trends

Psyence Biomedical's Income from Continuing Operations history runs 3 years deep, the most recent figure standing at 1504977.0 for Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Income (Continuing) (Qtr)
1 Alterity Therapeutics 925,601.88 Bn 925,601.85 Bn - -
2 Belite Bio 58,560.00 Bn 58,560.00 Bn - -26.94 Mn
3 Quantum Biopharma 17,284.41 Bn 17,284.40 Bn - -2.97 Mn
4 Legend Biotech 2,809.00 Bn 2,808.71 Bn 242.10 Mn 30.80 Mn
5 Evaxion A 1,334.43 Bn 1,334.42 Bn - -3.40 Mn
6 Akari Therapeutics 1,312.27 Bn 1,312.26 Bn - -14.46 Mn
7 Psyence Biomedical 212.16 Bn 212.16 Bn - -1.50 Mn
8 Vertex Pharmaceuticals 114.83 Bn 107.58 Bn 2.59 Bn 1.03 Bn
9 Abivax 91.96 Bn 91.96 Bn - -56.48 Mn
10 Regeneron Pharmaceuticals 63.43 Bn 54.67 Bn 3.31 Bn 727.20 Mn

Historic Data

Download Data
DateValue
Sep 30, 2025 -1.50 Mn
Sep 30, 2024 1.16 Mn
Mar 31, 2023 -3.23 Mn